Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
PMID 9610496
Plates were read on an Envision plate reader (PerkinElmer)
The SELECT cardiovascular outcomes trial published in 2023 added a cardiovascular benefit signal: semaglutide reduced major adverse cardiovascular events by 20% in overweight and obese patients with established cardiovascular disease, independent of diabetes status
The FDA label for semaglutide 2.4 mg mirrors these thresholds, which are consistent with the 2022 American Gastroenterological Association (AGA) guideline recommendations for pharmacotherapy in obesity [5]
Understanding Limitations and Alternatives Not Everyone Is a Candidate for Zepbound Patients with certain medical histories or non-obesity-related causes of OSA may not benefit from Zepbound
